{
    "nctId": "NCT05633654",
    "briefTitle": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)",
    "officialTitle": "A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1514,
    "primaryOutcomeMeasure": "Invasive Disease-free Survival (iDFS)",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \\> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:\n\n  * TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) \\< 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).\n* Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.\n* Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.\n* Adequate organ function.\n\nKey Exclusion Criteria:\n\n* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.\n* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior or concurrent treatment with any endocrine therapy agent.\n* Evidence of recurrent disease following preoperative therapy and surgery.\n* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.\n* Individuals with germline breast cancer gene (BRCA) mutations.\n* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \\< 50%\n* Active serious infections requiring anti-microbial therapy.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}